LDL accumulation is consistently and significantly increased by mevastatin treatments in primary AML cell samples, but less frequently increased by DNR or ARA-C treatments, although LDL increments are significantly correlated with cholesterol increments in DNR-treated AMLs. (A) All 18 AML cell samples showed significant LDL increments after mevastatin treatments, but only 5 of these samples significantly increased LDL accumulation after DNR and only 6 samples significantly increased LDL accumulation after ARA-C treatment. Mean LDL accumulation increments are plotted, error bars represent SEM, and Wilcoxon rank sum tests were used to compare means of treated and untreated aliquots ofAML samples. Bold horizontal line indicates mean. (B) Cholesterol increments were positively correlated with LDL accumulation increments in DNR-treated (r = 0.93; 95% CI, 0.34-0.99) and DNR plus statin cotreated AML samples (r = 0.92; 95% CI, 0.21-0.99), but not in ARA-C–treated (r =–0.18; 95% CI, –0.87 to 0.74) or ARA-C plus statin cotreated AML samples (r =–0.21; 95% CI –0.87 to 0.72).